Your browser doesn't support javascript.
loading
Cardiotoxicity risk with bortezomib versus lenalidomide for treatment of multiple myeloma: A propensity matched study of 1,790 patients.
Reneau, John C; Asante, Dennis; van Houten, Holly; Sangaralingham, Lindsey R; Buadi, Francis K; Lerman, Amir; Herrmann, Joerg.
Afiliação
  • Reneau JC; Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota.
  • Asante D; Department of Health Sciences Research, Biomedical Statistics and Informatics, Mayo Clinic, Rochester, Minnesota.
  • van Houten H; Mayo Clinic Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, Minnesota.
  • Sangaralingham LR; OptumLabs, Cambridge, Massachusetts.
  • Buadi FK; Mayo Clinic Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, Minnesota.
  • Lerman A; Division of Hematology, Mayo Clinic, Rochester, Minnesota.
  • Herrmann J; Department of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota.
Am J Hematol ; 92(2): E15-E17, 2017 02.
Article em En | MEDLINE | ID: mdl-27813147
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Talidomida / Bortezomib / Cardiopatias / Mieloma Múltiplo / Antineoplásicos Tipo de estudo: Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2017 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Talidomida / Bortezomib / Cardiopatias / Mieloma Múltiplo / Antineoplásicos Tipo de estudo: Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2017 Tipo de documento: Article